News | April 06, 2010

SBRT Survival Rates Higher Than in Conventional Radiation Therapy

Elekta Axesse SBRT linear accelerator.

April 6, 2010 - The three-year survival rate for patients receiving stereotactic body radiation therapy (SBRT) was 55.8 percent, compared to the 20-35 percent two-year to three-year overall survival rate for studies reporting results from conventional radiation therapy for similar patient groups, a recent study found.

Lead investigator, Robert Timmerman, M.D., conducted a study using SBRT to treat nearly 60 patients with inoperable early stage lung cancer. The study 2004-2006 Radiation Therapy Oncology Group (RTOG 0236) study was a Phase 2 North American trial of patients with nonsmall cell lung tumors where pre-existing medical conditions precluded surgical treatment.

According to Dr. Timmerman, the main finding in this study was the high rate of primary tumor control, which is 97.6 percent at three years. "SBRT as delivered in this trial provided more than double the rate of primary tumor control than previous reports describing conventional radiation therapy. Primary tumor control is essential for curing lung cancer," he said.

Dr. Timmerman and his team used Elekta SBRT solutions. The system is designed to integrate advanced technologies to enable a radiation therapy treatment technique that delivers highly sculpted dose distributions with exceptional precision.

For more information: www.elekta.com

Related Content

First Hospitals Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
News | Radiation Therapy | January 19, 2018
Accuray Inc. announced recently that the Heidelberg University Hospital in Heidelberg, Germany, and Oscar Lambret...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
Overlay Init